- Open Access
Direct transdifferentiation of spermatogonial stem cells to morphological, phenotypic and functional hepatocyte-like cells via the ERK1/2 and Smad2/3 signaling pathways and the inactivation of cyclin A, cyclin B and cyclin E
© Zhang et al.; licensee BioMed Central Ltd. 2013
- Received: 25 April 2013
- Accepted: 3 September 2013
- Published: 18 September 2013
Severe shortage of liver donors and hepatocytes highlights urgent requirement of extra-liver and stem cell source of hepatocytes for treating liver-related diseases. Here we hypothesized that spermatogonial stem cells (SSCs) can directly transdifferentiate to hepatic stem-like cells capable of differentiating into mature hepatocyte-like cells in vitro without an intervening pluripotent state.
SSCs first changed into hepatic stem-like cells since they resembled hepatic oval cells in morphology and expressed Ck8, Ck18, Ck7, Ck19, OV6, and albumin. Importantly, they co-expressed CK8 and CK19 but not ES cell markers. Hepatic stem-like cells derived from SSCs could differentiate into small hepatocytes based upon their morphological features and expression of numerous hepatic cell markers but lacking of bile epithelial cell hallmarks. Small hepatocytes were further coaxed to differentiate into mature hepatocyte-like cells, as identified by their morphological traits and strong expression of Ck8, Ck18, Cyp7a1, Hnf3b, Alb, Ta t, Ttr, albumin, and CYP1A2 but not Ck7 or CK19. Notably, these differentiated cells acquired functional attributes of hepatocyte-like cells because they secreted albumin, synthesized urea, and uptake and released indocyanine green. Moreover, phosphorylation of ERK1/2 and Smad2/3 rather than Akt was activated in hepatic stem cells and mature hepatocytes. Additionally, cyclin A, cyclin B and cyclin E transcripts and proteins but not cyclin D1 or CDK1 and CDK2 transcripts or proteins were reduced in mature hepatocyte-like cells or hepatic stem-like cells derived from SSCs compared to SSCs.
SSCs can transdifferentiate to hepatic stem-like cells capable of differentiating into cells with morphological, phenotypic and functional characteristics of mature hepatocytes via the activation of ERK1/2 and Smad2/3 signaling pathways and the inactivation of cyclin A, cyclin B and cyclin E. This study thus provides an invaluable source of mature hepatocytes for treating liver-related diseases and drug toxicity screening and offers novel insights into mechanisms of liver development and cell reprogramming.
- Spermatogonial stem cells
- Direct transdifferentiation
- Hepatic stem cells
- Mature hepatocytes
- Morphology and phenotype
- ERK1/2 and Smad2/3 signaling pathways
Liver cancer is one of most common tumors around the world and the majority of patients with this disease usually die within one year. Hepatitis B virus infected over 300 million people, which is a common cause of end-stage liver diseases including cirrhosis. The effective treatment for end-stage liver diseases is liver transplantation. However, there is a severe shortage of liver donors, which is the major obstacle for treatment of patients with end-stage liver diseases. Consequently, many patients suffering from end-stage liver diseases have to be on the waiting list and they die before liver transplantation can be performed. Hepatocytes’ transplantation is an alternative approach to restore liver function and cure liver congenital metabolic diseases[4, 5]. Nevertheless, human hepatocytes are scarce in number and have a very limited potential of proliferation. Therefore, it is crucial to seek a readily available source of hepatocytes from extra-liver tissues and/or stem cells that can be cultured and expanded in vitro to treat patients with end-stage liver diseases.
Hepatic stem cells can differentiate into functional hepatocytes. Nevertheless, the number of hepatic stem cells is very few in patients with end-stage liver diseases. Embryonic stem (ES) cells have been used to differentiate into hepatocytes. However, the availability of human ES cells is rather limited due to the ethic and safety issues. Recently, the induced pluripotent stem (iPS) cells have been utilized to generate functional hepatocytes[9, 10]. Nevertheless, it is cautious to use hepatocytes derived from iPS cells for clinical applications due to their genetic instability and using viral transduction for reprogramming somatic cells to pluripotency, which poses a potential tumor risk that could limit their use in regenerative medicine. Adult tissue stem cells can differentiate into mature cells with specific functions. One obvious advantage of using adult tissue stem cells is that there is no ethical issue compared to ES cells, and most importantly, certain adult tissue stem cells have multipotency to differentiate into various kinds of cells for regenerative medicine.
Spermatogonial stem cells (SSCs) are a subpopulation of type A spermatogonia in the testis. SSCs were previously regarded as unipotent stem cells since they were thought to differentiate into sperm only. However, this concept has recently been changed. Notably, recent studies have demonstrated that SSCs from both mouse and human testes can de-differentiate to become ES-like cells that can differentiate into various cell lineages of all three embryonic germ layers[11, 12], suggesting that SSCs have important implications in regenerative medicine. On the other hand, SSCs de-differentiate to become pluripotent ES-like cells, which may cause tumor since ES-like cells can form teratomas after transplantation. Recent study suggests that SSCs transdifferentiate into prostatic, uterine, and skin epithelium in vivo after transplantation. However, it remains unknown whether SSCs have the potential to transdifferentiate into other types of stem cells in vitro. In this study, we propose a novel concept that SSCs can directly transdifferentiate to hepatic stem cells in vitro capable of differentiating into mature hepatocytes, which achieves two significant endpoints. First of all, direct transdifferentiation of primary SSCs to hepatic stem cells without the process of de-differentiation to pluripotent ES-like cells and embryonic body formation could simplify the reprogramming procedure. Secondly, our direct programming of transdifferentiation using growth factors without gene transduction could be much safer to generate mature hepatocytes for cell therapy of chronic liver disease and metabolic abnormalities. Here we present detailed induction and differentiation protocols as well as molecular and cellular evidence supporting direct transdifferentiation of SSCs into hepatic stem-like cells that are able to differentiate into cells with morphological, phenotypic, and functional mature hepatocyte-like cells via the activation of ERK1/2 and Smad2/3 pathways.
Spermatogonial stem cell line C18-4 cells and culture
Spermatogonial stem cell line, namely C18-4 cells, was established by transfecting mouse SSCs with a plasmid expressing the SV40 large T antigen. C18-4 cells were cultured with Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F12 (DMEM/F12, Gibico, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibico), 2 mM L-glutamine (Invitrogen, Carlsbad, CA), and 100 unit/ml penicillin and streptomycin (Invitrogen). The cells were passed every 3-4 days and maintained at 34°C in a humidified 5% CO2 incubator.
Transdifferentiation of SSCs to hepatic stem-like cells and mature hepatocyte-like cells
Primary SSCs were isolated from the testes of 6-day-old BALB/c mice using two-step enzymatic digestion and magnetic activated cell sorting with an antibody to GFRA1 according to procedure as described previously. All animal care procedures were performed pursuant to the National Research Council’s Guide for the Care and Use of Laboratory Animals, China. Experimental protocols used were approved by the Renji Hospital Animal Care and Use Committee.
For further differentiation, transdifferentiated cells were cultured on 0.1% gelatin-coated tissue culture dishes with hepatocyte culture medium (HCM) plus EGF supplement (BD Bioscience, Bedford, MA) and 20 ng/ml hepatocyte growth factor (HGF, Peprotech). Medium was changed every 2 days and the cells were cultivated for 5 days. The differentiated cells were matured for another 5-10 days using HCM supplemented with 10 ng/ml HGF, 10 ng/ml Oncostain M (OSM, Peprotech), and 10-4 mM dexamethasone (Dex, Sigma-Aldrich, St. Louis, MO).
Transmission electron microscopy (TEM)
Hepatic stem-like cells and mature hepatocyte-like cells derived from SSCs were fixed in 2.5% w/v glutaraldehyde in 0.1 M cacodylate buffer. After extensive washing in PBS, the cells were post-fixed in 1% w/v OsO4 for 30 min, dehydrated in a graded solution of ethanol and embedded in Epon. Ultrathin sections were cut and examined under an electron microscope after staining with uranyl acetate and lead citrate.
Immunocytochemistry was performed on SSCs, the transdifferentiated cells, and the fully differentiated cells according to the procedure described previously. The cells were fixed with 4% paraformaldehyde and permeabilized in 0.4% triton-X 100 (Sigma-Aldrich) for 15 min. After washing with phosphate-buffered saline (PBS, Gibico), cells were blocked in 1% bovine serum albumin (BSA, Sigma-Aldrich) for 15 min and followed by incubation with primary antibodies at a dilution with 1:100 overnight at 4°C. Primary antibodies used were anti-VASA (Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-RET (Santa Cruz), anti-UCHL1 (BD Bioscience), anti-GFRA1 (Santa Cruz), anti-OV6 (R&D System), anti-CYP1A2 (Santa Cruz), anti-ALB (Novus Biologicals, Littleton, CO), anti-PLZF (abcam, Cambridge, MA), anti-SSEA-1(Chemicon, Temecula, CA), anti-SSEA-4 (Chemicon), anti-Nanog (Chemicon), or anti-TRA-1-81(Chemicon). After three washes with PBS, the cells were incubated with the secondary antibody, including FITC-conjugated or rhodamine-conjugated IgG (Jackson ImmunoResearch, West Grove, PA), at a 1:200 dilution for 45 min at room temperature. DAPI (4′-6-diamidino-2-phenylindole) was used to stain the nuclei, and the cells were observed for epifluorescence using fluorescence microscope (Nikon Eclipse Ti-S, Nikon Corporation, Tokyo, Japan). Double staining was performed to determine whether the cells derived from SSCs were co-expressing CK19 and CK8 using anti-CK19 (R&D System) and anti-CK8 (Santa Cruz).
Immunofluorescence was also carried out to determine the expression changes of phosphorylation of ERK1/2, Smad2, Stat3, and Akt in the C18-4 cells, the transdifferentiated cells, and differentiated cells using antibodies against phospho-ERK1/2 (Cell Signaling Technology, Inc., Danvers, MA), phospho-Smad2 (Cell Signaling Technology), phospho-Stat3 (Cell Signaling Technology), or phospho-Akt (Cell Signaling Technology).
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from C18-4 cells, the transdifferentiated cells, and the fully differentiated cells from C18-4 cells and primary SSCs using Trizol (Invitrogen). Reverse transcription (RT) was performed using First Strand cDNA Synthesis Kit (Fermentas, Lithuania) and PCR was performed according to the protocol as described previously. The forward and reverse primers and PCR products of the chosen genes, including Cytokine 8 (Ck8), Ck18, Ck7, Ck19, Cyp1a2, Cyp7a1, hepatocyte nuclear factor (Hnf)3b, Hnf4a, Albumin (Alb), tyrosine aminotransferase (Tat), transthyretin (Ttr), Cyclin A, Cyclin B, Cyclin D1, Cyclin E, CDK1, CDK2, c-fos, Oct-4, and Gapdh were designed and listed in Additional file1: Table S1. The PCR reaction started at 94°C for 5 min and was performed as follows: denaturation at 94°C for 30 sec, annealing at a temperature (Tm) as indicated in Additional file1: Table S1 for 45 sec, and elongation at 72°C for 45 sec. After 30 cycles, the samples were incubated for an additional 5 min at 72°C. PCR products were separated by electrophoresis on 1.2% agarose gels. The gels were exposed to chemiluminescence (Chemi-Doc XRS, Bio-Rad, Hercules, CA).
Hepatic stem-like cells derived from SSCs in the conditioned medium with or without MEK1 inhibitor PD98059 were first fixed with 1% paraformaldehyde, permeabilized by permeabilization buffer (eBioscience, San Diego, CA), and incubated with primary antibody to CK8. After washes, cells were incubated by FITC-coupled secondary antibody, and analyses were performed using Accuri C6 flow cytometer (Accuri Cytometers, Ann Arbor, MI) and Cflow software (Accuri Cytometers). The SSCs-derived cells without primary antibody but were incubated by FITC-coupled secondary antibody served as a negative control.
Cells were lysed with RIPA buffer (Santa Cruz) for 30 min on ice. After 30 min lysis on ice, cell lysates were cleared by centrifugation at 12,000 g, and the concentration of protein was measured by BCA kit (Dingguo Company, China). Ten micrograms of cell lysate from each sample were used for SDS-PAGE (Bio-Rad Laboratories, Richmond, CA), and Western blots were performed according to the protocol we described previously. The chosen antibody included CK8, phos-ERK1/2 (Santa Cruz), phos-Smad2 (Santa Cruz), Smad2/3 (Santa Cruz), cyclin A (Santa Cruz), cyclin B (Santa Cruz), cyclin D1 (Santa Cruz), cyclin E (Santa Cruz), and ACTB (beta-actin) (IMGENEX Corp). After extensive washes in PBS, the blots were detected by chemiluminescence (Chemi-Doc XRS, Bio-Rad, Hercules, CA).
Albumin synthesis of hepatocyte-like cells derived from SSCs by ELISA
Primary mouse hepatocytes were isolated from liver tissues using 0.03% collagenase IV and 0.025 EDTA and cultured in William’s E + 100 nM insulin + 15% FBS according to procedure as described previously. Culture medium from SSCs and the differentiated cells was collected over 2 days from equivalent numbers of cells. Albumin production in the medium from the differentiated cells and primary mouse hepatocytes was determined by mouse Albumin ELISA Quantitation Kit (Alpha Diagnostic Intl. Inc, San Antonio, TX) according to the manufacturer’s instructions. Albumin secretion was normalized to per 105 cells.
Urea assays of hepatocyte-like cells derived from SSCs
After exposure of the cells to 2 mM ammonium chloride (Sigma-Aldrich) for 24 h, urea productions in the culture media of SSCs, mature hepatocyte-like cells derived from SSCs, and primary mouse hepatocytes were measured using Urea Assay Kit (Biovision, Mountain View, CA). Fresh culture medium supplemented with 2 mM ammonium chloride was used as a negative control. Urea production was expressed as mM urea nitrogen per 105 cells within 24 h.
Uptake and release of indocyanine green (ICG) of hepatocyte-like cells derived from SSCs
Indocyanine green (ICG) (Sigma-Aldrich) was suspended in DMSO (Sigma-Aldrich) for a stock at 100 mg/ml and freshly diluted in HCM to a working concentration of 1 mg/ml. Hepatocyte-like cells derived from SSCs and primary mouse hepatocytes were incubated with the diluted ICG for 30 min at 37°C. After extensive washes, positive foci were counted and photographed under the microscope, and the cells were returned to HCM and incubated for 20 h. Release of cellular ICG stain was examined, and undifferentiated C18-4 cells were used as a negative control while primary mouse hepatocytes served as a positive control.
All experiments were performed independently at least 3 times. All the values were presented as mean ± SEM, and statistically significant differences (p< 0.05) between SSCs and differentiated cells were determined using the analysis of variance (ANOVA) and a 2-tailed t-test.
Direct transdifferentiation of SSCs to hepatic stem-like cells
We first verified the identity of the C18-4 cells using various markers for germ cells and SSCs. Immunocytochemistry revealed that C18-4 cells expressed VASA (Additional file2: Figure S1A), UCHL1 (Additional file2: Figure S1B), GFRA1 (Additional file2: Figure S1C), and RET (Additional file2: Figure S1D), suggesting that the C18-4 cells are phenotypically SSCs.
To induce the transdifferentiation of C18-4 cells to hepatic stem-like cells, 6 conditioned media supplemented with various growth factors and liver tissue extract (Figure 1A and Additional file3: Figure S2B-2F) were employed. Among these culture conditions, the combination of growth factors, including Nodal, Wnt3a, and bFGF, was the best approach for inducing the transdifferentiation of C18-4 cells. Other approaches led to a high death rate of the cells (Additional file3: Figure S2C, 2D, and 2F), or had little effect on transdifferentiation (Additional file3: Figure S2B and 2E). The C18-4 cells proliferated rapidly when cultured with 10% FBS (Additional file3: Figure S2A). To avoid cell overgrowth, culture medium was changed into a low concentration of FBS (0.5-2%) in DMEM/F12 supplemented with Nodal, Wnt3a, and bFGF (Figure 1B). After 10 days of culture, the morphology of cells was obviously changed and became oval and stereoscopic in shape (Figure 1C), which is similar to hepatic oval cells (termed hepatic stem cells). Transmission electron microscopy revealed that these cells had an ovoid nucleus with condensed chromatin, a higher ratio of nuclei to cytoplasm, and few organelles including immature mitochondria (Mi) and rough endoplasmic reticulum (Er) (Figure 1F). Compared to mature hepatocytes, oval cells were relatively small since they had a median diameter of 8 μm.
Differentiation of SSCs-derived hepatic stem-like cells into small hepatocytes
Differentiation of SSCs-derived hepatic stem-like cells into mature hepatocyte-like cells
Hepatic stem cells are defined in part by their ability to differentiate into mature hepatocytes. We made endeavors to further induce the differentiation of hepatic stem-like cells derived from SSCs using HCM supplemented with HGF, OSM, and Dex. In morphology, small hepatocytes derived from SSCs changed to become polygonal appearance with tight cell-cell contacts and a low ratio of cellular nucleus to cytoplasm (Figure 1E), which showed an attribute of mature hepatocytes. In addition, our ultrastructural observations provided more convincing evidence that small hepatocytes further differentiated into mature hepatocyte-like cells since they contained well-developed organelles such as mitochondria (Mi), endoplasmic reticulum (Er), lysosome (Ly) and Golgi apparatus (Go) (Figure 1G).
Functional assays of mature hepatocyte-like cells derived from SSCs
ERK1/2 and Smad2/3 but not Akt signaling pathways were activated during the transdifferentiation of SSCs into mature hepatocyte-like cells
C-fos and Oct-4 transcripts were activated during the transdifferentiation of SSCs into mature hepatocyte-like cells
We also probed the c-fos transcript when SSCs transdifferentiated into mature hepatocyte-like cells. RT-PCR analysis showed that c-fos mRNA was increased significantly in mature hepatocyte-like cells derived from SSCs compared to hepatic stem-like cells or SSCs (Figure 7C), suggesting that c-fos transcript is activated during the transdifferentiation of mouse SSCs into mature hepatocyte-like cells. Oct-4 transcript was reduced in hepatic stem-like cells compared to SSCs (Figure 8D), whereas it was enhanced in mature hepatocyte-like cells derived from SSCs compared to hepatic stem-like cells (Figure 8D).
Cyclin A, cyclin B, and cyclin E but not cyclin D1, CDK1, or CDK2 were inactivated during the transdifferentiation of SSCs into mature hepatocyte-like cells
We further explored the cyclin A, cyclin B, cyclin D1, cyclin E, CDK1 and CDK2 transcripts, as well as cyclin A, cyclin B, cyclin D1 and cyclin E proteins when SSCs transdifferentiated into mature hepatocyte-like cells. RT-PCR analysis revealed that mRNA of cyclin A, cyclin B and cyclin E was reduced significantly in mature hepatocyte-like cells derived from SSCs compared to hepatic stem-like cells or SSCs (Figure 7D), whereas there is no significant change in the transcripts of cyclin D1, CDK1, and CDK2 (Figure 7D and E). Western blots further displayed that cyclin A, cyclin B and cyclin E proteins but not cyclin D1 protein were diminished in mature hepatocyte-like cells or hepatic stem-like cells derived from SSCs compared to SSCs (Figure 7E). Considered together, these data implicate that cyclin A, cyclin B, and cyclin E but not cyclin D1, CDK1, or CDK2 are inactivated when mouse SSCs transdifferentiate into mature hepatocyte-like cells.
Lack of mature hepatocytes limits their wider application of hepatocyte transplantation and tissue engineering for the treatment of liver diseases. It is imperative to generate mature and functional hepatocytes independent of donor liver organs and from stem cells. Several studies have shown that hepatocytes can be generated from ES cells and hepatic stem cells. Recently, human iPS cells have been used to differentiate into hepatocytes[9, 10]. However, hepatocytes derived from human iPS cells involve a complicated process. Of great concern, the use of iPS cells for cell therapies is hampered by their tumor-forming risk, due to reprogramming of somatic cells by gene transfer using viral vectors and their genetic instability. Therefore, more attention has been paid to generate hepatocytes from extra-liver source and adult stem cells. Here we have for the first time demonstrated that SSCs can directly transdifferentiate in vitro into the cells with morphological, phenotypic and functional attributes of mature hepatocyte-like cells.
We have previously identified the C18-4 cells as SSCs[16, 17]. Here we further verified the identity of SSCs using a variety of markers for germ cells and SSCs. VASA has been recognized as a germ cell marker while UCHL1 is a hallmark for spermatogonia. GFRA1 and Ret are co-receptors for GDNF and markers for SSCs[23, 24]. We found that C18-4 cells expressed VASA, UCHL1, GFRA1, and Ret. These data together with our previous studies indicate that C18-4 cells possess phenotypic characteristics of SSCs.
We used 6 different conditioned media to induce the transdifferentiation of SSCs. Among them, we optimized the defined condition with Nodal, Wnt3a, and bFGF for inducing the transdifferentiation of C18-4 cells into cells with morphological and phenotypic characteristics of hepatic stem-like cells. In morphology and ultrastructure, these cells derived from C18-4 cells resembled hepatic oval cells. In phenotypes, the cells derived from SSC line and primary SSCs expressed Ck8, Ck18, Ck7, and Ck19, and were co-expressing CK8 and CK19. CK8 and Ck18 are markers for hepatic cells while Ck7 and CK19 have been regarded as hallmarks for bile epithelial cells. Moreover, the cells obtained from SSCs strongly expressed OV6, an antigen specific for rodent hepatic stem cells[19, 20]. Taken together, these results suggest that the cells generated from SSCs expressed both hepatocyte and cholangiocyte markers, indicating that they retained the bipotential nature of hepatic stem cells. Notably, we found the cells derived from SSCs didn’t express the ES cell markers, including SSEA-1, SSEA-4, Nanog, or TRA-1-81, suggesting that these cells are not reprogrammed to ES cells.
Significantly, Nodal, Wnt3a, and bFGF induce a very high efficiency of SSC transdifferentiation into hepatic stem-like cells, as evidenced by our observations that more than 97% of cells derived from SSCs were positive for CK18. These growth factors play important roles during embryogenesis and organogenesis of the liver. Nodal plays an essential role at the earliest stages of endoderm formation, and Nodal regulates early endoderm development in vivo. The Wnt pathway is required for liver growth and development. Wnt3a promotes endodermal induction from human iPS cells, and it is important for hepatic cell function. Wnt3a is present at critical stages of human liver development and it elicits a rapid and efficient cellular progression of iPS cells to hepatic endoderm. bFGF is secreted by the mesoderm and it is the first factor that commits the foregut endoderm to form liver primordium. Mesodermal cytokines induce foregut specification into hepatic endoderm and followed by FGF signaling into the liver bud[29, 30]. This is the first report showing that Nodal synergized with Wnt3a and bFGF to induce SSC transdifferentiation into hepatic stem-like cells.
HGF is required for liver development and it is associated with the ontogenesis of liver. Hepatocyte differentiation can be induced from mesenchymal stem cells by HGF and other growth factors. Consistent with these findings, here we found that HGF and HCM could efficiently induce hepatic stem-like cells derived from SSCs to differentiate into small hepatocytes. Morphologically and phenotypically different from hepatic stem cells, small hepatocytes were round and had round nuclei but did not express CK19. Meanwhile, small hepatocytes expressed Ck8, Ck18, Cyp7a1, Hnf3b, and Alb transcript, suggesting that they possess partial characteristics of hepatocytes. HGF promotes hepatic growth and differentiation while OSM and Dex have been implicated in the maturation of the hepatocytes. Here we found that HGF acted synergistically with OSM and Dex to effectively induce hepatic stem cells derived from SSCs to differentiate into cells with morphologic, phenotypic, and functional features of mature hepatocyte-like cells. In morphology, these cells became polygonal with a low nucleus/cytoplasm ratio. In phenotypes, these cells derived from C18-4 cells and primary SSCs expressed numerous hepatocyte markers, including CK8, Ck18, Cyp7a1, Hnf4a, Hnf3b, ALB, CYP1A2, Tat, and Ttr, but were negative for CK19 or Ck7, hallmarks for bile epithelial cells. Of great interest are our findings that the cells generated from SSCs had the functional attributes of mature hepatocyte-like cells since they could synthesize albumin, produce urea, as well as uptake and release ICG.
It is unclear what signaling pathways are involved in cellular transdifferentiation. ERK1/2 and Smad2 pathways regulate a variety of cellular functions, including cell proliferation, differentiation, and cell cycle progression[16, 17]. We found that ERK1/2 and Smad2 but not Akt signaling pathways were activated during the transdifferentiation of SSCs into mature hepatocyte-like cells, which offers a novel insight into the mechanisms underlying liver development and stem cell reprogramming. The ability to transdifferentiate SSCs using patients’ own adult testis tissues directly into hepatic stem cells without having to go through de-differentiation to pluripotent ES-like cells and embryonic body formation is essential for reducing differentiation procedures and improving safety for their clinical applications. Our study not only outlines novel approaches for transdifferentiation of hepatic stem-like cells with high efficiency but also offers new methods for rapidly and directly differentiating hepatic stem cells into mature and functional hepatocyte-like cells, using only growth factors without genetic manipulation. As such, the approaches presented here could contribute to overall objective of using patient-specific SSCs to generate mature and functional hepatocytes for cell transplantation and tissue engineering for the treatment of liver-related diseases as well as for hepatotoxicity screening of pharmaceutical drug development.
This study was supported by a grant from National Science Foundation of China (31171422), key grants from National Nature Science Foundation of China (31230048 and 81130038), Shanghai Pujiang Program (11PJ1406400), The Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, grants from Chinese Ministry of Science and Technology (2012CB966800, 2013CB947901, 2014CB943101, 2013CB945600), and a key grant from the Science and Technology Commission of Shanghai Municipality (12JC1405900).
- Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.PubMedView ArticleGoogle Scholar
- Williams R: Global challenges in liver disease. Hepatology. 2006, 44: 521-526. 10.1002/hep.21347.PubMedView ArticleGoogle Scholar
- Fuster J, Charco R, Llovet JM, et al: Liver transplantation in hepatocellular carcinoma. Transpl Int. 2005, 18: 278-282. 10.1111/j.1432-2277.2004.00046.x.PubMedView ArticleGoogle Scholar
- Michalopoulos GK, DeFrances MC: Liver regeneration. Science. 1997, 276: 60-66. 10.1126/science.276.5309.60.PubMedView ArticleGoogle Scholar
- Muraca M, Gerunda G, Neri D, et al: Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet. 2002, 359: 317-318. 10.1016/S0140-6736(02)07529-3.PubMedView ArticleGoogle Scholar
- Golding M, Sarraf CE, Lalani EN, et al: Oval cell differentiation into hepatocytes in the acetylaminofluorene-treated regenerating rat liver. Hepatology. 1995, 22: 1243-1253.PubMedGoogle Scholar
- Choi D, Oh HJ, Chang UJ, et al: In vivo differentiation of mouse embryonic stem cells into hepatocytes. Cell Transplant. 2002, 11: 359-368.PubMedGoogle Scholar
- Gallicano GI, Mishra L: Hepatocytes from induced pluripotent stem cells: a giant leap forward for hepatology. Hepatology. 2010, 51: 20-22. 10.1002/hep.23474.PubMedView ArticleGoogle Scholar
- Chen YF, Tseng CY, Wang HW, et al: Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012, 55: 1193-1203. 10.1002/hep.24790.PubMed CentralPubMedView ArticleGoogle Scholar
- Takayama K, Inamura M, Kawabata K, et al: Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction. J Hepatol. 2012, 57: 628-636. 10.1016/j.jhep.2012.04.038.PubMedView ArticleGoogle Scholar
- Guan K, Nayernia K, Maier LS, et al: Pluripotency of spermatogonial stem cells from adult mouse testis. Nature. 2006, 440: 1199-1203. 10.1038/nature04697.PubMedView ArticleGoogle Scholar
- Conrad S, Renninger M, Hennenlotter J, et al: Generation of pluripotent stem cells from adult human testis. Nature. 2008, 456: 344-349. 10.1038/nature07404.PubMedView ArticleGoogle Scholar
- Simon L, Ekman GC, Kostereva N, et al: Direct transdifferentiation of stem/progenitor spermatogonia into reproductive and nonreproductive tissues of all germ layers. Stem Cells. 2009, 27: 1666-1675. 10.1002/stem.93.PubMed CentralPubMedView ArticleGoogle Scholar
- Hofmann MC, Braydich-Stolle L, Dettin L, et al: Immortalization of mouse germ line stem cells. Stem Cells. 2005, 23: 200-210. 10.1634/stemcells.2003-0036.PubMed CentralPubMedView ArticleGoogle Scholar
- He Z, Kokkinaki M, Jiang J, et al: Isolation, characterization, and culture of human spermatogonia. Biol Reprod. 2010, 82: 363-372. 10.1095/biolreprod.109.078550.PubMed CentralPubMedView ArticleGoogle Scholar
- He Z, Jiang J, Kokkinaki M, et al: Gdnf upregulates c-Fos transcription via the Ras/Erk1/2 pathway to promote mouse spermatogonial stem cell proliferation. Stem Cells. 2008, 26: 266-278. 10.1634/stemcells.2007-0436.PubMed CentralPubMedView ArticleGoogle Scholar
- He Z, Jiang J, Kokkinaki M, et al: Nodal signaling via an autocrine pathway promotes proliferation of mouse spermatogonial stem/progenitor cells through Smad2/3 and Oct-4 activation. Stem Cells. 2009, 27: 2580-2590. 10.1002/stem.198.PubMed CentralPubMedView ArticleGoogle Scholar
- He ZP, Tan WQ, Tang YF, et al: Differentiation of putative hepatic stem cells derived from adult rats into mature hepatocytes in the presence of epidermal growth factor and hepatocyte growth factor. Differentiation. 2003, 71: 281-290. 10.1046/j.1432-0436.2003.7104505.x.PubMedView ArticleGoogle Scholar
- Mishra L, Banker T, Murray J, et al: Liver stem cells and hepatocellular carcinoma. Hepatology. 2009, 49: 318-329. 10.1002/hep.22704.PubMed CentralPubMedView ArticleGoogle Scholar
- Crosby HA, Hubscher SG, Joplin RE, et al: Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology. 1998, 28: 980-985. 10.1002/hep.510280412.PubMedView ArticleGoogle Scholar
- Toyooka Y, Tsunekawa N, Takahashi Y, et al: Expression and intracellular localization of mouse Vasa-homologue protein during germ cell development. Mech Dev. 2000, 93: 139-149. 10.1016/S0925-4773(00)00283-5.PubMedView ArticleGoogle Scholar
- Luo J, Megee S, Rathi R, et al: Protein gene product 9.5 is a spermatogonia-specific marker in the pig testis: application to enrichment and culture of porcine spermatogonia. Mol Reprod Dev. 2006, 73: 1531-1540. 10.1002/mrd.20529.PubMedView ArticleGoogle Scholar
- Buageaw A, Sukhwani M, Ben-Yehudah A, et al: GDNF family receptor alpha1 phenotype of spermatogonial stem cells in immature mouse testes. Biol Reprod. 2005, 73: 1011-1016. 10.1095/biolreprod.105.043810.PubMedView ArticleGoogle Scholar
- Naughton CK, Jain S, Strickland AM, et al: Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biol Reprod. 2006, 74: 314-321. 10.1095/biolreprod.105.047365.PubMedView ArticleGoogle Scholar
- D’Amour KA, Agulnick AD, Eliazer S, et al: Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol. 2005, 23: 1534-1541. 10.1038/nbt1163.PubMedView ArticleGoogle Scholar
- Hussain SZ, Sneddon T, Tan X, et al: Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res. 2004, 292: 157-169. 10.1016/j.yexcr.2003.08.020.PubMedView ArticleGoogle Scholar
- Yeh JR, Zhang X, Nagano MC: Indirect effects of Wnt3a/beta-catenin signalling support mouse spermatogonial stem cells in vitro. PLoS One. 2012, 7: e40002-10.1371/journal.pone.0040002.PubMed CentralPubMedView ArticleGoogle Scholar
- Lavon N, Benvenisty N: Study of hepatocyte differentiation using embryonic stem cells. J Cell Biochem. 2005, 96: 1193-1202. 10.1002/jcb.20590.PubMedView ArticleGoogle Scholar
- Sancho-Bru P, Roelandt P, Narain N, et al: Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells. J Hepatol. 2011, 54: 98-107. 10.1016/j.jhep.2010.06.014.PubMedView ArticleGoogle Scholar
- Jung J, Zheng M, Goldfarb M, et al: Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science. 1999, 284: 1998-2003. 10.1126/science.284.5422.1998.PubMedView ArticleGoogle Scholar
- Schmidt C, Bladt F, Goedecke S, et al: Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995, 373: 699-702. 10.1038/373699a0.PubMedView ArticleGoogle Scholar
- Lee KD, Kuo TK, Whang-Peng J, et al: In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology. 2004, 40: 1275-1284. 10.1002/hep.20469.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.